Replies to post #126821 on Biotech Values

[dav1234]

it appears so, 100 + 150, i personally dont know what percentage of market those strengths comprise, but from your tone, the lower dosages are a larger part of the market.

not sure if vials that can be used at lower dosages if needed

[rwwine]

Regardless, as I understand things, the profit share MNTA receives still changes from 45% to 10-12%.

[DewDiligence]

I’m interpreting this to mean that Amphastar got approval for all dosage forms of Lovenox, not just the vial formulations (which are commercially inconsequential). My initial reaction was the same as yours, FWIW.